Advertisement

Topics

FDA orphan status given to Reviva's idiopathic pulmonary fibrosis therapy

06:19 EDT 16 Apr 2018 | SmartBrief

The FDA gave Reviva Pharmaceutical's RP5063 orphan status for treatment of idiopathic pulmonary fibrosis.  -More

Original Article: FDA orphan status given to Reviva's idiopathic pulmonary fibrosis therapy

NEXT ARTICLE

More From BioPortfolio on "FDA orphan status given to Reviva's idiopathic pulmonary fibrosis therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...